Skip to main
IBRX
IBRX logo

ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio (IBRX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ImmunityBio reported a notable 21% increase in net product revenue for Q4 2024, reaching $7.2 million, driven primarily by the accelerating sales of ANKTIVA following its FDA approval. The drug exhibits strong durable response rates, with 51.1% and 48.3% rates at 18 and 24 months, respectively, highlighting its potential for expansion into first-line non-muscle invasive bladder cancer (NMIBC) treatment. Additionally, collaborations, regulatory submissions in Europe, and projected revenue growth from ANKTIVA—expected to reach $137.4 million in 2025 and potentially $4.3 billion by 2034—indicate a robust pathway for future financial performance.

Bears say

ImmunityBio has experienced operating losses since its inception, with prospects for achieving profitability remaining distant, potentially spanning several years. The company's significant debt and revenue interest liability pose risks to its cash flow and limit its capacity to raise additional capital, which could further complicate its financial stability. Additionally, delays in regulatory approvals and the sluggish uptake of its therapies, particularly in the context of increasing demand for treatments amid rising cancer incidence, contribute to an overall negative sentiment regarding the firm’s stock performance.

ImmunityBio (IBRX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ImmunityBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ImmunityBio (IBRX) Forecast

Analysts have given ImmunityBio (IBRX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, ImmunityBio (IBRX) has a Strong Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ImmunityBio (IBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.